This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

RNA Leaders APAC
October 15-16, 2025
Marina Bay Sands, Sands Expo & Convention CentreSingapore

Dr. Lisa Ooi
Assistant CEO at A*STAR
Speaker

Profile

Dr Lisa Ooi is currently the Assistant Chief Executive of the A*STAR's Biomedical ResearchCouncil (BMRC). She drives the implementation of A*STAR's strategies and initiatives in thebiomedical domains to create industry and societal impact, and to build long-term R&Dcapabilities for Singapore. Spanning nine research institutes, the mission-directed biomedicalR&D portfolio she oversees leverages core research areas such as bioprocessing, genomics,proteomics, molecular and cell biology, bioengineering, nanotechnology and computationalbiology.Dr Ooi was the Chief Operating Officer at Hummingbird Bioscience, where she oversaw thecompany's pipeline and portfolio, with a focus on the development and commercialisation ofnew therapies and building of differentiated technology platforms.Prior to Hummingbird, Dr Ooi was the Vice President (Healthcare and Wellness) at the SingaporeEconomic Development Board (EDB), where she partnered global leading biotech and medtechcompanies in innovation. She was also on the COVID-19 Therapeutics and Vaccines review paneland a member of the Expert Committee on COVID-19 Vaccination, appointed by the Ministry ofHealth (MOH) to make recommendations to the government on its COVID-19 vaccinationstrategy.Dr Ooi has extensive experience in the biomedical industry having led drug discovery anddevelopment projects, engaging with international experts and regulators. She was formerlyscientific director at ASLAN pharmaceuticals and had been with the Biomedical SciencesIndustry Partnership Office (BMSIPO), which catalyses academic-industry biomedical researchand clinical partnerships across Singapore's ecosystem. She had also previously worked with theplanning and policy division at A*STAR and was attached to the alliance management division atBayer Pharmaceuticals.Dr Ooi holds a PhD from Stanford University, in Chemical and System Biology. She received theGlaxo Wellcome Scholarship from the EDB to pursue an undergraduate degree in Biochemistryand a master's degree in Chemical Engineering.

Agenda Sessions

  • Keynote Address: Insights into Singapore's journey in mRNA innovation

    8:45am
  • Driving Innovation for the Next-Generation RNA Therapeutics in the Asia-Pacific Region

    9:35am